0 of 5 questions completed
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
0 of 5 questions answered correctly
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
You must score 0% to continue. Please click the link below to re-take the quiz
1. Please list your last name and zip code:
2. What is your specialty?
3. How many patients with IBD do you treat each week?
4. The FDA recently added a black box warning for an increased risk of venous thromboembolic events (VTE) in rheumatoid arthritis patients on high-dose tofacitinib (10 mg PO BID). A post-hoc analysis of the clinical trial data (OCTAVE and open-label, long-term extension trials) in 1,157 patients with UC (Sandborn, et al. Aliment Pharmacol Ther. 2019;50(10):1068-1076) showed which of the following?
5. Your patient, a 27-year-old female patient with moderately severe UC, is a primary nonresponder to infliximab and vedolizumab. After a discussion of the risks, benefits, and alternatives, you and the patient decide to initiate therapy with tofacitinib, an oral small-molecule Janus kinase inhibitor. When reviewing preventive care, you recommend the recombinant zoster vaccine, Shingrix. Which of the following statements is correct?